| 1 | Combination Product: Ravulizumab OBDS (Ultomiris) | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  62 62 💬
 | 
| 2 | Ravulizumab (Ultomiris) | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [7]  2 2, 11, 13, 50, 62, 66, 109 💬
 | 
| 3 | Ultomiris | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [6]  2 2, 11, 13, 50, 62, 66 💬
 | 
| 4 | ULTOMIRIS - 300 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 3 ML (100 MG / ML) - 1 FLACONCINO | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  62 62 💬
 | 
| 5 | Ultomiris 1,100 mg/11 mL | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  11 11 💬
 | 
| 6 | Ultomiris 300 mg/30 ml | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  66 66 💬
 | 
| 7 | Ultomiris 300mg/30ml | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  62 62 💬
 | 
| 8 | ULTOMIRIS ™ (ravulizumab-cwvz) | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  62 62 💬
 | 
| 9 | ULTOMIRIS® | [1]  Ravulizumab Ravulizumab (Ultomiris) | [1]  Ravulizumab 
                
                    Ravulizumab
                
             (Ultomiris) 💬
 | [1]  C5 C5 💬
 | [11]  Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | [1]  13 13 💬
 |